Happy new year everyone.
Just a note to add the announcement from Thomson Reuters about our Markush Agreement is formally out, full text below, link to press release at PRNewswire.
I also wanted to confirm that we will be hosting the Markush Forum meeting at the back of the European and US UGM's this year. The call for papers for the European event (May 17-18) has gone out already and I ask you consider presenting for the UGM and/or Markush Forum. More details below.
Best regards for 2011
Alex
PS - if you want to unsubscribe from these mailings just reply to this with unsubscribe in the subject line or body
European UGM. Details and abstract submission. Markush forum details
- Dates: May 17-18
- Location: Danubius Health Spa Resort on Margit island, Budapest, Hungary.
- Satellite meetings (same location)
- Markush Forum: May 19th am
- User and Developer training: May 16th
*****************************Press release text****************************
Thomson
Reuters and ChemAxon Partner to Help Speed Drug Discovery for Life Science
Researchers
For
the first time ever, R&D end users can search and analyze Thomson Reuters
trusted Markush chemical structures and patents with ChemAxon’s cheminformatics
applications to streamline workflow productivity
London,
UK and Budapest, Hungary – 4 January 2011 – The IP Solutions
business of Thomson Reuters®, the leader in intellectual property
research and analysis solutions, and ChemAxon, the leader in cheminformatics
software for the life sciences industry, today announced a strategic
partnership whereby Thomson Reuters is providing its chemical IP Data Feeds – Markush
Structures and patent data to users of ChemAxon’s JChem chemical software
platform. This search and analysis solution will speed drug discovery and allow
life science researchers to easily integrate critical content into their existing
systems and workflow.
The Markush structures from
Thomson Reuters are part of the company’s Derwent World Patents Index®
(DWPISM) database, the world’s most trusted and authoritative source
of global patent information. The Markush database contains essential data on
the relationship or “families” of 550,000 patents, making it the world’s leading
source for life sciences patentability research, competitive intelligence and
IP screening. ChemAxon’s JChem software allows
life science professionals to structure and visualize chemical compounds for
property prediction, virtual synthesis, screening and drug design. Through this
partnership R&D end users can now research and analyze Markush structures
using ChemAxon’s JChem chemical software platform, a means they had no access
to before. The ability to quickly
retrieve this information will now allow R&D end users to save time and
capitalize on R&D investment.
“The ability to search and visualize
complex chemical patents is critical to the work of life science R&D
professionals. To date, however, this has been a challenge as there wasn’t a tool
that enabled R&D end users to do this type of work themselves,” said Cindy
Poulos, vice president of product management, Thomson Reuters. “Through this
partnership, Thomson Reuters and ChemAxon are making a comprehensive worldwide database
of chemical compounds widely accessible in a user-friendly, flexible format to
end users.”
“The Markush structures
database has become a vital backbone of pharmaceutical research in the digital
age,” said Alex Drjver, CEO of ChemAxon.
“By delivering this data directly to the end user in an intuitive,
flexible format, our clients have access to the functionality and data necessary
to stay competitive in today’s fast-paced, complex marketplace.”
The Thomson Reuters IP
Data Feed - Markush Structures database is indexed from 550,000 patent
families, plus 1.7 million related, exemplified, specific compounds. It includes patents for pharmaceuticals,
agrochemicals and general chemistry spanning 26 patent-issuing
authorities. Markush data is integrated
with high-quality patent summary data from DWPI, enabling access to enhanced patent
abstracts, family and assignee details, and relevant bibliographic data. For more information, contact Steve
Hajkowski, product manager, Thomson Reuters, at steve.hajkowski__at__thomsonreuters__.__com
About ChemAxon Ltd
ChemAxon is a leader
in providing cheminformatics software development platforms and applications
for the biotechnology, pharmaceutical and agrochemical industries. With core
capabilities for structure visualization, search and management, property
prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon
active interaction with users and software portability to create powerful, cost
effective cross platform solutions and programming interfaces to power modern
cheminformatics and chemical communication.
About Thomson Reuters
Thomson Reuters is the world's leading source of
intelligent information for businesses and professionals. We combine
industry expertise with innovative technology to deliver critical information
to leading decision makers in the financial, legal, tax and accounting,
healthcare and science and media markets, powered by the world's most trusted
news organization. With headquarters in New York
and major operations in London and Eagan, Minnesota,
Thomson Reuters employs 55,000 people and operates in over 100 countries. For
more information, go to www.thomsonreuters.com.
**********************************END**************************************